Rahime ŞİMŞEK, Gökalp ÇETİN, Busra ÇETİN, Betül ÇOLAK, Gökcen BİRLİK DEMİREL, Demet CANSARAN DUMAN, Nefise AKÇELİK

A new perspective for biological activities of novel hexahydroquinoline derivatives

Cancer is a systemic disease that occurs by various molecular mechanisms and its certain treatment has not been achieved yet. Antimicrobial drugs are the only option for the treatment of infections cause by bacteria and fungi. However, most microorganisms might develop resistantance against these drugs. 1,4-Dihydropyridine (1,4-DHP) is a partially saturated form of pyridine ring which shows calcium channel modulator activity. In addition to this activity of 1,4-DHPs and analog compounds such as hexahydroquinoline (HHQ), other activities have also been investigated. In this study, two new HHQ derivatives were synthesized to obtain a lead compound which has anticancer and antimicrobial activity. The structures of the synthesized compounds were proved by spectral methods. These HHQ derivatives compounds were conjugated to magnetic nanoparticles to investigate the changes in their anticancer and antimicrobial activities. For this purpose, firstly, we synthesized silica-coated magnetic nanoparticles. The silica-coated magnetic nanoparticles were conjugated with HHQ to enhance anticancer and antimicrobial activities. Anticancer and antimicrobial activity studies were carried out for both compounds and magnetic nanoparticle (MNP) forms. In addition, the physicochemical and pharmacokinetic properties, lipophilicity, water solubility and druglikeness of the compounds were determined in silico. Altogether, our data indicate that the new hexahydroquinoline derivatives have anticancer activity and the magnetic nanoparticle form led to increasing to this activity.

PDF

___

[1] The top 10 causes of death. World Health Organization. https://www.who.int/news-room/factsheets/ detail/the-top-10-causes-of-death (accessed September 22, 2021). [2] Breast cancer statistics: World cancer research fund international. WCRF International 2021. https://www.wcrf.org/dietandcancer/cancer-trends/breast-cancer-statistics (accessed September 22, 2021).
[3] Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and Taxane. Mayo Clinic Proceedings 2009; 84(6): 533–545. [CrossRef]
[4] Alqaraghuli HG, Kashanian S, Rafipour R. A review on targeting nanoparticles for breast cancer. Curr Pharm Biotechnol. 2019; 20(13): 1087–1107. [CrossRef]
[5] Cancer. World Health Organization. https://www.who.int/health-topics/cancer#tab=tab_1 (accessed September 22, 2021).
[6] Sharma VK, Singh SK. Synthesis, utility and medicinal importance of 1,2- & -1,4-dihydropyridines. RSC Adv. 2017; 7(5): 2682–2732. [CrossRef]
[7] Fleckenstein A, Breemen Cvan. Cardiovascular Effects of Dihydropyridine-Type Calcium Antagonists and Agonists. In: Cardiovascular effects of dihydropyridine-type calcium antagonists and agonists 50 tabellen ; Bayer-Symposium IX, held at Boppard, Germany, Oct 3 - 6, 1984. Berlin u.a., Boppard: Springer; 1985. p. 3–31.
[8] Safak C, Simsek R. Fused 1,4-dihydropyridines as potential calcium modulatory compounds. Mini-Rev Med Chem. 2006; 6: 747–755. [CrossRef]
[9] Kumar RS, Idhayadhulla A, Nasser AJA, Selvin J. Synthesis and antimicrobial activity of a new series of 1,4-dihydropyridine derivatives. J Serbian Chem Soc. 2011; 76(1): 1–11. [CrossRef]
[10] Komoda H, Inoue T, Node K. Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clin Exp Hypertens. 2010; 32(2): 121–128. [CrossRef]
[11] Milkovic L, Vukovic T, Zarkovic N, Tatzber F, Bisenieks E, Kalme Z, et al. Antioxidative 1,4- dihydropyridine derivatives modulate oxidative stress and growth of human osteoblast-like cells in vitro. Antioxidants. 2018; 7(9): 1–23. [CrossRef]
[12] Gordeev MF, Patel D V., Wu J, Gordon EM. Approaches to combinatorial synthesis of heterocycles: Solid phase synthesis of pyridines and pyrido[2,3-d]pyrimidines. Tetrahedron Lett. 1996; 37(27): 4643–4646. [CrossRef]
[13] Gordeev MF, Patel D V., England BP, Jonnalagadda S, Combs JD, Gordon EM. Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers. Bioorganic Med Chem. 1998; 6(7): 883–889. [CrossRef]
[14] Zafar AM, Iqbal A, Ashraf M, Aslam S, Naureen S, Aslam N, et al. Synthesis and in vitro cholinesterase inhibitory potential of dihydropyridine derivatives. Pak J Pharm Sci. 2019; 32(3 (Suppl.)): 1155–1162.
[15] Baydar E, Gündüz MG, Krishna VS, Şimşek R, Sriram D, Yıldırım SÖ, et al. Synthesis, crystal structure and antimycobacterial activities of 4-indolyl-1,4-dihydropyridine derivatives possessing various ester groups. Res Chem Intermed. 2017; 43(12): 7471–7489. [CrossRef]
[16] Swarnalatha G, Prasanthi G, Sirisha N, Madhusudhana Chetty C. 1,4-Dihydropyridines: A multtifunctional molecule- a review. Int J ChemTech Res. 2011; 3(1): 75–89.
[17] Tasaka S, Ohmori H, Gomi N, Iino M, Machida T, Kiue A, et al. Synthesis and structure-activity analysis of novel dihydropyridine derivatives to overcome multidrug resistance. Bioorg Med Chem Lett. 2001; 11(2): 275–277. [CrossRef]
[18] Vijesh AM, Isloor AM, Peethambar SK, Shivananda KN, Arulmoli T, Isloor NA. Hantzsch reaction: Synthesis and characterization of some new 1,4-dihydropyridine derivatives as potent antimicrobial and antioxidant agents. Eur J Med Chem 2011; 46(11): 5591–5597. [CrossRef]
[19] Schade D, Lanier M, Willems E, Okolotowicz K, Bushway P, Wahlquist C, et al. Synthesis and SAR of bannulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling. J Med Chem 2012; 55(22): 9946–9957. [CrossRef]
[20] Ioan P, Carosati E, Micucci M, Cruciani G, Broccatelli F, S. Zhorov B, et al. 1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives (Part 1): Action in Ion Channels and GPCRs. Curr Med Chem. 2011; 18(32): 4901–4922. [CrossRef]
[21] Ozer EK, Gunduz MG, El-Khouly A, Simsek R, Safak C, Sara Y, et al. Synthesis of fused 1,4- dihydropyridines as potential calcium channel blockers. Turkish J Biochem. 2018; 43(6): 578–586. [CrossRef]
[22] Ranjbar S, Edraki N, Firuzi O, Khoshneviszadeh M, Miri R. 5-Oxo-hexahydroquinoline: an attractive scaffold with diverse biological activities. Mol Divers 2019; 23(2): 471–508. [CrossRef]
[23] Jadhvar SC, Kasraliker HM, Goswami S V., Chakrawar A V., Bhusare SR. One-pot synthesis and evaluation of anticancer activity of polyhydroquinoline derivatives catalyzed by [Msim]Cl. Res Chem Intermed. 2017; 43(12): 7211–7221. [CrossRef]
[24] Abdel-Gawad SM, El-Gaby MSA, Heiba HI, Aly HM, Ghorab MM. Synthesis and radiation stability of some new biologically active hydroquinoline and pyrimido[4,5-b]quinoline derivatives. J Chinese Chem Soc. 2005; 52(6): 1227–1236. [CrossRef]
[25] Thumar NJ, Patel MP. Synthesis and antimicrobial activity of some new N-substituted quinoline derivatives of 1H-pyrazole. Arch Pharm (Weinheim). 2011; 344(2): 91–101. [CrossRef]
[26] Singh H, Sindhu J, Khurana JM, Sharma C, Aneja KR. A facile eco-friendly one-pot five-component synthesis of novel 1,2,3-triazole-linked pentasubstituted 1,4-dihydropyridines and their biological and photophysical studies. Aust J Chem 2013; 66(9): 1088-1096. [CrossRef]
[27] Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol. 2018; 9: 1300. [CrossRef]
[28] Rostom SAF, Faidallah HM, Radwan MF, Badr MH. Bifunctional ethyl 2-amino-4-methylthiazole-5- carboxylate derivatives: Synthesis and in vitro biological evaluation as antimicrobial and anticancer agents. Eur J Med Chem 2014; 76: 170–181. [CrossRef]
[29] Ferreira M, Sousa J, Pais A, Vitorino C. The role of magnetic nanoparticles in cancer nanotheranostics. Materials 2020; 13(2): 1–25. [CrossRef]
[30] Niemirowicz K, Durnaś B, Tokajuk G, Głuszek K, Wilczewska AZ, Misztalewska I, et al. Magnetic nanoparticles as a drug delivery system that enhance fungicidal activity of polyene antibiotics. Nanomedicine. 2016; 12(8): 2395–2404. [CrossRef]
[31] Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. Applications of Fluorine in Medicinal Chemistry. J Med Chem. 2015; 58(21): 8315–8359. [CrossRef]
[32] Alkabban FM. Breast cancer. StatPearls [Internet] 2021. https://www.ncbi.nlm.nih.gov/books/NBK482286/ (accessed September 22, 2021).
[33] Abotaleb M, Kubatka P, Caprnda M, Varghese E, Zolakova B, Zubor P, et al. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. Biomed Pharmacother. 2018; 101: 458–477. [CrossRef]
[34] Hai NH, Phu ND, Luong NH, Chau N, Chinh HD, Hoang LH, et al. Mechanism for sustainable magnetic nanoparticles under ambient conditions. J Korean Phys Soc. 2008; 52(5): 1327–1331. [CrossRef]
[35] Pham XH, Hahm E, Kim HM, Son BS, Jo A, An J, et al. Silica-coated magnetic iron oxide nanoparticles grafted onto graphene oxide for protein isolation. Nanomaterials. 2020; 10(1): 1–14. [CrossRef] [36] Curtis AE, Smith TA, Ziganshin BA, Elefteriades JA. The Mystery of the Z-Score. AORTA. 2016;4(4):124– 130 [CrossRef]
[37] Niemirowicz-Laskowska K, Głuszek K, Piktel E, Pajuste K, Durnaś B, Król G, et al. Bactericidal and immunomodulatory properties of magnetic nanoparticles functionalized by 1,4-dihydropyridines. Int J Nanomedicine. 2018; 13: 3411–3424. [CrossRef]
[38] Fahami A, Beall GW, Betancourt T. Synthesis, bioactivity and zeta potential investigations of chlorine and fluorine substituted hydroxyapatite. Mater Sci Eng C. 2016; 59: 78–85. [CrossRef]
[39] Swissadme. SwissADME. http://www.swissadme.ch/ (accessed September 22, 2021).
[40] Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, et al. Rate-limited steps of human oral absorption and QSAR studies. Pharm Res. 2002; 19(10): 1446–1457. [CrossRef]
[41] Fromm MF. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther. 2000; 38(2): 69–74. [CrossRef]
[42] Daina A, Zoete V. A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016; 11(11): 1117–1121. [CrossRef] This is an open access article which is publicly available on our journal’s website under Institutional